雅努斯激酶抑制剂用于脱发区域:系统性审查和元分析
Ming Liu1,2, Ya Gao1,2, Yuan Yuan3,4
1Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China.
JAMA network open
|June 27, 2023
概括
简氏激酶 (JAK) 抑制剂在治疗白发症 (AA) 中显示出有效性,导致显著的头发再生. 口服JAK抑制剂与局部配方相比,表现优越,具有可接受的安全性.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 大发脱发症 (AA) 是一种常见的自身免疫性疾病,影响毛囊.
- 氏激酶 (JAK) 抑制剂已成为AA的潜在治疗方法,但强有力的证据有限.
研究的目的:
- 系统地评估JAK抑制剂在治疗白发症的疗效和安全性.
- 为了比较口服与局部JAK抑制剂的有效性.
主要方法:
- 进行了随机临床试验 (RCT) 的元分析,搜索了MEDLINE,Embase和CENTRAL数据库,直到2022年8月.
- 包括7个涉及1710名患者的RCT,分析了脱发症工具 (SALT) 严重性得分和与治疗相关的不良事件 (AE).
- 使用推,评估,开发和评估 (GRADE) 的分级方法来评估证据的确定性.
主要成果:
- 与安慰剂 (低确定性证据) 相比,JAK抑制剂显著增加了患者在SALT得分中实现50%和90%的改善的比例.
- 证据的中等确定性表明,JAK抑制剂导致SALT得分比基线下降更大.
- 与安慰剂相比,使用JAK抑制剂时没有观察到与治疗相关的副作用的显著增加 (高确定性证据).
- 口服JAK抑制剂显示出比安慰剂更大的疗效,而局部JAK抑制剂与安慰剂没有显著差异.
结论:
- 雅克抑制剂与有形脱发症患者的头发再生有关.
- 口服JAK抑制剂在AA治疗中似乎比局部配方更有效.
- 虽然一般安全且耐受良好,但需要进行长期研究,以充分确定JAK抑制剂对AA的有效性和安全性.
相关概念视频
The JAK-STAT Signaling Pathway
9.0K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.0K
PI3K/mTOR/AKT Signaling Pathway
3.7K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.7K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
177
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
177
NF-κB-dependent Signaling Pathway
7.5K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.5K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
201
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
201
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K


